Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286

Kirstin Brown,Kaley M Wilburn,Christine R Montague, J.C. Grigg,Olalla Sanz,Esther Pérez-Herrán,David Barros,Lluís Ballell,Brian C. VanderVen,Lindsay D. Eltis

Antimicrobial Agents and Chemotherapy（2023）

引用 3|浏览8

暂无评分

摘要

Despite the deployment of combination tuberculosis (TB) chemotherapy, efforts to identify shorter, nonrelapsing treatments have resulted in limited success. Recent evidence indicates that GSK2556286 (GSK286), which acts via Rv1625c, a membrane-bound adenylyl cyclase in Mycobacterium tuberculosis , shortens treatment in rodents relative to standard of care drugs.

查看译文

关键词

<i>mycobacterium tuberculosis</i>,cholesterol catabolism,drug,amp-mediated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要